Adapalène

Non disponible en dehors du Royaume-Uni et de l'Irlande

General description

A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RARβ and RARγ over RARα (Kd = 34, 130, and 1100 nM, respectively; AC₅₀ = 2.3, 9.3, and 22 nM, respectively, in COS-7-based reporter assays) without appreciable affinity toward cytosolic retinoic acid binding proteins CRABP I/II (Kd >>1 µM) or detectable activity toward RXRα (AC₅₀ >1 µM). The biological activity and pharmaceutical efficacy of ADA are generally shown to be superior to those of ATRA/Tretinoin (Cat. No. 554720) both in vitro and in vivo.

A cell-permeable naphthoic acid compound that exhibits selective affinity and agonistic potency toward RARβ and RARγ over RARα (Kd = 34, 130, and 1100 nM, respectively; AC₅₀ = 2.3, 9.3, and 22 nM, respectively, in COS-7-based reporter assays) without appreciable affinity toward cytosolic retinoic acid binding proteins CRABP I/II (Kd >>1 M) or detectable activity toward RXRα (AC₅₀ >1 M). The biological activity and pharmaceutical efficacy of ADA are generally shown to be superior to those of ATRA/Tretinoin both in vitro and in vivo.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Irby, C.E., et al. 2008. J. Adolesc. Health43, 421.Ocker, M., et al. 2003. Int. J. Cancer107, 453.Kim, M.J., et al. 2000. J. Invest. Dermatol.114, 349.Shroot, B., et al. 1997. J. Am. Acad. Dermatol.36, S96.

Reconstitution

Following initial thaw, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Standard Handling (A)